Genfit S.A. (OTCMKTS:GNFTF) Short Interest Update

Genfit S.A. (OTCMKTS:GNFTF) was the recipient of a significant decrease in short interest in January. As of January 15th, there was short interest totalling 500 shares, a decrease of 88.1% from the December 31st total of 4,200 shares. Based on an average trading volume of 400 shares, the days-to-cover ratio is presently 1.3 days.

Genfit Price Performance

Genfit stock remained flat at $3.54 during trading hours on Tuesday. Genfit has a 1 year low of $2.95 and a 1 year high of $5.55. The firm has a fifty day moving average of $4.45 and a 200-day moving average of $4.79.

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.